Viking Therapeutics, Inc. (VKTX): Cash & Equivalents
$165.81M
As of 2025-12-31
$125.75M
As of 2026-06-30
+65.4%
3-year compound annual growth
+41.6%
5-year compound annual growth
n/m
10-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $165.81M | +521.6% | 2026-02-11, Balance as of period end |
| 2024-12-31 | $26.68M | -51.9% | 2026-02-11, Balance as of period end |
| 2023-12-31 | $55.52M | +51.6% | 2025-02-26, Balance as of period end |
| 2022-12-31 | $36.63M | +38.9% | 2024-02-07, Balance as of period end |
| 2021-12-31 | $26.37M | -9.4% | 2023-02-10, Balance as of period end |
| 2020-12-31 | $29.12M | +247.6% | 2022-02-09, Balance as of period end |
| 2019-12-31 | $8.38M | -66.2% | 2021-02-17, Balance as of period end |
| 2018-12-31 | $24.78M | +175.7% | 2020-02-26, Balance as of period end |
| 2017-12-31 | $8.99M | +192.2% | 2019-03-13, Balance as of period end |
| 2016-12-31 | $3.08M | +300.2% | 2018-03-07, Balance as of period end |
| 2015-12-31 | $768.5K | +1.7% | 2017-03-21, Balance as of period end |
| 2014-12-31 | $755.9K | n/a | 2016-03-08, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Viking Therapeutics, Inc. (VKTX) | 2025-12-31 | $165.81M | +521.6% |
| Abbott Laboratories (ABT) | 2025-12-31 | $8.52B | +11.9% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $10.21B | -1.3% |
| TherapeuticsMD, Inc. (TXMD) | 2024-12-31 | $5.06M | +16.9% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $7.27B | +122.4% |
| Pfizer Inc (PFE) | 2025-12-31 | $1.14B | +9.5% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $19.71B | -18.2% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $93.89M | +10.9% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $14.56B | +10.0% |
Compare VKTX, ABT, BMY, TXMD side by side · Screen every company in Pharmaceutical Preparations ↗